Effective January 1, 2016, the American Heart Association will implement an automated award process for Get With The Guidelines®-AFIB program
What does that mean for the hospitals?
- Hospital no longer will have submit an on-line paper version of their award application
- Data will be transferred quarterly via Quintiles to AHA, the data will be aggregated by hospital, and award eligibility will be determined
- Time of compliance will be on the calendar year (January to December) for all award levels
- Hospitals will be notified in May if they qualify for award
What is the hospital responsibility under the new automated award process?
- Hospitals must have all prior year (calendar year) data entered into the PMT by March 31.
- Complete Quality Improvement Programs Permission Form (document) and return to your local QSI director (Only necessary to complete if not done so in past or you have name change request)
- Hospital will be notified by local QSI staff in May if they qualify for award
Don’t miss out on these recognition opportunities. We thank you for your continued dedication to improving patient care, if you have any questions please contact your local representative or email GWTGAwards@heart.org
Hospitals that participate actively and consistently in Get With The Guidelines®--AFIB are eligible for public recognition. Participating in GWTG-S is the first level of recognition. It acknowledges program participation and entry of baseline data into the Patient Management ToolTM. View the Get With The guidelines Participating Hospital award permission for (document).
With The Guidelines-AFIB Achievement Measures. The different levels reflect the amount of time for which the hospital demonstrates performance.
- Bronze: recognizes performance of 90 consecutive days.
- Silver recognizes performance of 12 consecutive months.
- Gold recognizes performance of 24 consecutive months or more.
The Achievement Measures are embedded in the Patient Management Tool*. They are:
- ACEI/ARB at discharge for LVSD: Percent of patients with left ventricular systolic dysfunction (LVSD) and without both angiotensin converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB) contraindications who are prescribed an ACEI or ARB at hospital discharge. For purposes of this measure, LVSD is defined as chart documentation of a left ventricular ejection fraction (LVEF) less than 40% or a narrative description of left ventricular function (LVF) consistent with moderate or severe systolic dysfunction.
- Assessment of thromboembolic risk factors: Percent of patients with nonvalvular atrial fibrillation or atrial flutter in whom assessment of thromboembolic risk factors using the CHADS2 risk criteria has been documented.
- Beta blocker at discharge: Percent of patients with left ventricular systolic dysfunction (LVSD) prescribed a beta blocker at hospital discharge.
- Discharged on FDA-approved anticoagulation therapy: Percent of patients discharged on warfarin or other anticoagulant drug that is FDA approved for the prevention of thromboembolism for all patients with nonvalvular atrial fibrillation or atrial flutter at high risk for thromboembolism, according to CHADS2 risk stratification.
- PT/INR planned follow-up: Percent of patients discharged on warfarin who have PT/INR follow-up planned prior to hospital discharge.
- Statin at discharge in AF patients with CAD, CVA/TIA or PVD: Percent of patients with either CAD, CVA/TIA, PAD or diabetes who were prescribed a statin at hospital discharge.
Please note: Recognition criteria are subject to change based on program enhancements
* The Patient Management ToolTM is powered by Outcome, A Quintiles Company, Cambridge, Mass